Your browser doesn't support javascript.
loading
Response to Letter to Editor Regarding "Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma".
Oluwole, Olalekan O; Jansen, Jeroen P; Lin, Vincent W; Chan, Keith; Keeping, Sam; Navale, Lynn; Locke, Frederick L.
Affiliation
  • Oluwole OO; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee. Electronic address: olalekan.oluwole@vumc.org.
  • Jansen JP; Precision HEOR, Oakland, California.
  • Lin VW; Kite Pharma, a Gilead Company, Santa Monica, California.
  • Chan K; Precision HEOR, Vancouver, British Columbia, Canada.
  • Keeping S; Precision HEOR, Vancouver, British Columbia, Canada.
  • Navale L; Kite Pharma, a Gilead Company, Santa Monica, California.
  • Locke FL; Moffitt Cancer Center, Tampa, Florida.
Biol Blood Marrow Transplant ; 26(12): e335-e336, 2020 12.
Article in En | MEDLINE | ID: mdl-32950694
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Immunotherapy, Adoptive / Lymphoma, B-Cell Limits: Humans Language: En Journal: Biol Blood Marrow Transplant Journal subject: HEMATOLOGIA / TRANSPLANTE Year: 2020 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Immunotherapy, Adoptive / Lymphoma, B-Cell Limits: Humans Language: En Journal: Biol Blood Marrow Transplant Journal subject: HEMATOLOGIA / TRANSPLANTE Year: 2020 Type: Article